Liver stiffness and fibrosis-4 alone better predict liver events compared with aspartate aminotransferase to platelet ratio index in a cohort of human immunodeficiency virus and hepatitis C virus co-infected patients from ANRS CO13 HEPAVIH cohort.


Journal

European journal of gastroenterology & hepatology
ISSN: 1473-5687
Titre abrégé: Eur J Gastroenterol Hepatol
Pays: England
ID NLM: 9000874

Informations de publication

Date de publication:
Nov 2019
Historique:
pubmed: 30 4 2019
medline: 7 10 2020
entrez: 30 4 2019
Statut: ppublish

Résumé

HIV/hepatitis C virus (HCV) co-infection leads to major complications, and noninvasive markers developed to stage liver fibrosis could be used as prognostic markers. We aimed to compare the performances of liver stiffness (LS), fibrosis-4 (FIB-4), and aspartate aminotransferase to platelet ratio index (APRI) to predict liver-related events in HIV/HCV co-infected patients. HIV/HCV co-infected patients from the ANRS CO13 HEPAVIH cohort were included if they had LS, FIB-4, and APRI measurements done in a window of 3 months. Primary outcome was the time between inclusion and occurrence of a liver-related event. Univariable and multivariable Fine and Gray models were performed. Predictive performances were compared by the area under the receiver operating characteristic (AUROC) differences after correction of optimistic by bootstrap samples. Best cutoffs to predict liver-related events were estimated by sensitivity and specificity maximization. A total of 998 patients were included. Overall, 70.7% were men. Their median age was 46.8 years. According to LS value, 204 (20.4%) patients had cirrhosis. Overall, 39 patients experienced at least one liver-related event. In univariable analysis, LS AUROC curve was significantly superior to FIB-4 and APRI AUROC curves, being 87.9, 78.2, and 75.0%, respectively. After adjustment on age, CD4 levels, and insulin resistance, no differences were observed. The best cutoffs to identify patients at low or high risk of liver-related events were below 8.5, 1.00, and 0.35 and above 16.5, 4.00, and 1.75 for LS, FIB-4, and APRI, respectively. To predict HCV-related events, APRI had lower performance than LS and FIB-4. FIB-4 is as good as LS to predict HCV-related events, suggesting that it can be used for the management of HIV/HCV co-infected patients and replace LS.

Identifiants

pubmed: 31033848
doi: 10.1097/MEG.0000000000001408
doi:

Substances chimiques

Aspartate Aminotransferases EC 2.6.1.1
Alanine Transaminase EC 2.6.1.2

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

1387-1396

Auteurs

Mathieu Chalouni (M)

Bordeaux Population Health Research Center, ISPED, Inserm, Team MORPH3EUS, UMR 1219, Bordeaux University.

Philippe Sogni (P)

Liver Unit, Paris Public Hospitals, Cochin Hospital, INSERM U-1223, PasteurInstitute, Paris-Descartes University.

Patrick Miailhes (P)

Infectious and Tropical Disease Unit, University Hospital Center Lyon, de la Croix Rousse Hospital, Lyon.

Karine Lacombe (K)

Infectious and Tropical Disease Unit, Paris Public Hospitals, Saint-Antoine Hospital.
UMR S1136, Pierre Louis Epidemiology andPublic Health Institute, Pierre and Marie Curie University.

Isabelle Poizot-Martin (I)

INSERM, U912 (SE4S), IRD, UMR-S912- ORS PACA, Regional Health Observatory Provence Alpes Côte d'Azur.
APHM Sainte-Marguerite, Clinical Immunohematology Unit, Aix Marseille University, Marseille.

Julie Chas (J)

Infectious and Tropical Disease Unit, Paris Public Hospitals de Paris, Tenon Hospital.

Daniel Vittecoq (D)

Infectious and Tropical Disease Unit, Paris Public Hospitals, Bicêtre Hospital, University Hospitals Paris Sud.
Paris Sud University.

Didier Neau (D)

Infectious and Tropical Disease Unit, Bordeaux, University Hospital Center, Pellegrin Hospital.
UniveBordeaux University.

Hugues Aumaitre (H)

Infectious and Tropical Disease Unit, Perpignan Hospital Center, Perpignan.

Laurent Alric (L)

Purpan Hospital, Internal Medicine, Toulouse University Hospital Center.
Toulouse III University.

Lionel Piroth (L)

Department of Infectiology, Dijon University Hospital Center.
Bourgogne University, Dijon.

Olivier Bouchaud (O)

Infectious and Tropical Disease Unit, Paris Publics Hospitals, Avicenne Hospital.
Paris 13 Nord University,Bobigny.

Christine Katlama (C)

Department of Internal Medicine and Clinical Immunology, Paris Public Hospitals, Pitié-Salpétrière Hospital.

Philippe Morlat (P)

UniveBordeaux University.
Internal Medicine Unit, Saint-André Hospital, Bordeaux University Hospital Center.

Caroline Lascoux-Combe (C)

Infectious and Tropical Disease Unit, Paris Publics Hospitals, Saint-Louis Hospitals.

Anne Gervais (A)

Infectious and Tropical Disease Unit, AP-HP, Bichat Claude Bernard Hospital.

Alissa Naqvi (A)

Nice University Hospital Center, Infectiology Center, Archet 1 Hospital.

Eric Rosenthal (E)

Nice-Sophia Antipolis University, Nice, France.

Daniel Garipuy (D)

Medicine Unit, Joseph Ducuing Hospital.

Karl Barange (K)

Gastroenterology and Hepatology Unit, Purpan Hospital, Toulouse University Hospital Center, Toulouse.

Laure Esterle (L)

Bordeaux Population Health Research Center, ISPED, Inserm, Team MORPH3EUS, UMR 1219, Bordeaux University.

Dominique Salmon (D)

Infectious and Tropical Disease Unit, Paris Publics Hospitals, Cochin Hospital.
Paris Descartes University, Paris.

Linda Wittkop (L)

Bordeaux Population Health Research Center, ISPED, Inserm, Team MORPH3EUS, UMR 1219, Bordeaux University.
Medical Information Unit, Public Health Pole, Bordeaux University Hospital Center, Bordeaux.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH